Targeted ablation of parathyroidal tissue is provided through hyperthermia adjuvant therapy. An in situ localization of parathyroidal tissue is obtained. A temperature-sensitive adjuvant is instilled into the parathyroidal tissue. Hyperthermia is therapeutically induced within the parathyroidal tissue. Heat-inducing energy is targeted into the parathyroidal tissue, which selectively includes the temperature-sensitive adjuvant. Application of the heat-inducing energy to the parathyroidal tissue is continued over a therapeutic range. In a further embodiment, the targeted ablation of the parathyroidal tissue is provided through hypothermia adjuvant therapy with the targeted use of cold-inducing energy.

A medical inductive heating apparatus (10) for heating at least a portion of a prosthetic or implant. The apparatus (10) has at least one external induction coil, the external induction coil being external to a body or housing of the apparatus (10). The coil (12) is sized and dimensioned to be smaller than a body portion associated with the prosthetic or implant.

The present invention relates to an apparatus and a method for targeted drug delivery by use of a drug substance comprising a drug and magnetic particles. The apparatus comprises selection means for generating a magnetic selection field (50) having a pattern in space of its magnetic field strength such that a first sub-zone (52) having a low magnetic field strength where the magnetization of the magnetic particles is not saturated and a second sub-zone having a higher magnetic field strength where the magnetization of the magnetic particles is saturated are formed in a field of view (28), drive means for changing the position in space of the two sub-zones (52, 54) in the field of view (28) by means of a magnetic drive field so that the magnetization of the magnetic particles changes locally, and a control unit (150) for controlling said drive means to change the position in space of the two sub-zones (52, 54) such that after administration of the drug substance the first sub-zone (52) is moved through a surrounding area (320) arranged around a target area (310) except through the target area (310) itself, said surrounding area (320) representing a potentially affected volume and/or having a predetermined maximal distance from said target area (310).

Metallofullerene monocrystalline nanoparticles are used as tumor vascular disrupting agents. The monocrystalline nanoparticles are water-soluble metallofullerene nanoparticles with negative charges on their surfaces. The particle sizes range from 50 to 250 nanometers. The nanomaterials are able to absorb outside radiation energy, and transform it into heat energy. The volumes rapidly expand when temperature reaches a phase transformation point. For treatment, metallofullerene monocrystalline nanoparticles are administrated to a tumor-bearing organism via injection. The metallofullerene monocrystalline nanoparticles reach tumor sites via blood circulation, and are retained at the tumor sites. The monocrystalline nanoparticles of metallofullerene accumulate heat and the temperature increases under outside radiation energy. The volumes sharply expand when the temperature exceeds a critical point of phase transition thereof, thereby causing changes in the morphologies, structures or functions of endothelium cells of tumor vessels.

A system combines hyperthermia and radiation treatments in a single treatment modality by using a radioactive seed having magnetic, ferromagnetic, or ferrimagnetic properties.

A nanocomposite for detection and treatment of a target of interest including tumor cells or pathogens includes at least one nanostructure, each nanostructure having a core and a shell surrounding the core; a reporter assembled on the shell of each nanostructure; and a layer of a treating agent and a targeting agent conjugated to the reporter. In use, the nanocomposite targets to the target of interest according to the targeting agent and releases the treating agent and the nanostructure therein for therapeutic treatment of the target of interest, and the target of interest transmits at least one signature responsive to the reporter for detection of the target of interest.

The present disclosure provides devices, systems and methods for hyperthermia cancer treatment by supplying ferromagnetic nanoparticles to a target area having or suspected of having cancer cells, the ferromagnetic nanoparticles are configured to attach to the cancer cells and heat by absorbing magnetic energy, and radiating the target area with microwaves such that the target area is within a nearfield range of the radiated microwave, and the microwave radiation nearfield is magnetically biased such that the ratio of magnetic energy to electric energy is greater than 1.

Methods and apparatuses are provided for reducing sweat production via, for example, the removal, disablement, and incapacitation of sweat glands in the epidermis, dermis and subdermal tissue regions of a patient. In one embodiment, a method of treating a patient is provided which involves identifying a patient having a condition of excessive sweating, positioning an energy delivery device proximate to a skin tissue of the patient and delivering energy to sweat glands to halt secretion of sweat. The energy delivery device may include microwave delivery devices, RF delivery devices, and cryogenic therapy devices. Some embodiments may include using a cooling element for avoiding destruction of non-target tissue and/or a suction device to localize treatment at specific portions of the skin fold.

A composition including magnetic nanoparticles for use in the treatment of a tissue volume including pathological cells in an individual, wherein a portion only of the tissue volume is occupied by the magnetic nanoparticles upon administration of the composition to the individual and the magnetic nanoparticles are excited by radiation.

Products, compositions, systems, and methods for modifying a target structure which mediates or is associated with a biological activity, including treatment of conditions, disorders, or diseases mediated by or associated with a target structure, such as a virus, cell, subcellular structure or extracellular structure. The methods may be performed in situ in a non-invasive manner by placing a nanoparticle having a metallic shell on at least a fraction of a surface in a vicinity of a target structure in a subject and applying an initiation energy to a subject thus producing an effect on or change to the target structure directly or via a modulation agent. The nanoparticle is configured, upon exposure to a first wavelength λ.sub.1, to generate a second wavelength λ.sub.2 of radiation having a higher energy than the first wavelength λ.sub.1. The methods may further be performed by application of an initiation energy to a subject in situ to activate a pharmaceutical agent directly or via an energy modulation agent, optionally in the presence of one or more plasmonics active agents, thus producing an effect on or change to the target structure. Kits containing products or compositions formulated or configured and systems for use in practicing these methods.